CytoSorb Reduction of Free Hemoglobin During Cardiac Surgery

CytoSorb Reduction of Free Hemoglobin During Cardiac Surgery

Prospective, multi-center, randomized, feasibility clinical study. Subjects will be randomized in a 1:1 ratio to either standard of care (SOC) alone or standard of care and treatment with the CytoSorb® device.

Inclusion Criteria:

• Elective, cardiac surgery requiring cardiopulmonary bypass with anticipated duration of >180 minutes

Exclusion Criteria:

• Platelet count < 20,000/ uL
• Body mass index <18
• Pregnant women
• Life expectancy of <14 days
• End stage organ disease
• Active infection
• Undergoing cardiac transplant or ventricular assist device explant, isolated primary coronary artery bypass grafting (CABG) or single valve procedure
• Contraindication to anticoagulation with heparin
• Declined informed consent